With the U.S. Food and Drug Administration's May approval of Nucala (mepolizumab) for adults with COPD, we wanted to spotlight a clinical trial based around the pharmacological management of COPD, particularly one using a biologic intervention. 

What we found was the recently launched, and currently still recruiting, trial sponsored by GlaxoSmithKline: Depemokimab as an Extended Treatment Duration Biologic in Adults with COPD and Type 2 Inflammation. Depemokimab is a long-acting interleukin-5 antagonist. The trial kicked off on June 23, 2025, and has an estimated primary completion currently set for August 2029. This trial (ENDURA-2) has a sister trial (ENDURA-1) which is also currently taking place and recruiting. 

The trial is currently accepting adults who are 40–80 years old and older who have elevated blood eosinophil count, and who have moderate-to-severe COPD. These adults should also have a COPD assessment test score of 10 or higher, be a current or former smoker (>=10 pack-years), be on optimized inhaler therapy, and have a BMI >=16 kh/m^2. Consult the trial's full inclusion criteria for more specific details regarding patient eligibility.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

Study Details | Source

  • Sponsor: GlaxoSmithKline
  • Official Description: Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
  • Enrollment: 960
  • Intervention(s): Depemokimab, placebo
  • Primary Outcome Measure(s): Annualized Rate of Moderate/Severe Exacerbations
  • Anticipated Completion: August 21, 2029

We highly value your input and welcome any thoughts or insights you may have on this topic. Additionally, we encourage you to sign up for alerts to stay informed on the latest published guidelines and articles. Thank you for your continued support and engagement in advancing medical research and treatment options.

Copyright © 2025 Guideline Central, all rights reserved.